Qilu Pharmaceutical Co., Ltd. has seven manufacturing sites covering an area over 1,750,000m². Four sites have been approved by USFDA, EDQM, MHRA of UK, MHLW of Japan, TGA of Australia, MCC of South Africa, and other national regulatory authorities respectively for API (including sterile API) and Finished Dosage Forms. Another two sites are under construction and will be in operation in 2010. Dedicated facilities are serving for Oncology products, Penicillins, Cephalosporins and Beta-lactam inhibitor e.g. Tazobactam.